CNS Pharmaceuticals (CNSP) AI Stock Analysis

• Market Cap: $3.23M
• Dividend Yield: N/A
• Average Volume (3M): 16.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.52
• Revenue Growth: N/A
• EPS Growth: 99.87%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.76
• Shares Outstanding: 620,290
• 10 Day Avg. Volume: 15,052
• 30 Day Avg. Volume: 16,543
• PEG Ratio: 0.04
• Price to Book (P/B): 3.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.34
• Enterprise Value/Market Cap: -2.12
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.76K
• Enterprise Value/Ebitda: 0.52
• 1Y Price Target: $20.00
• Price Target Upside: 232.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $5.00 ▼(-16.81% Downside)

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and sizeable cash burn indicating continued financing needs), partially offset by low balance-sheet leverage. Technicals are modestly supportive in the near term (above key short/intermediate moving averages), but longer-term trend and MACD remain weak, and valuation is constrained by negative earnings.

Positive Factors

Focused CNS oncology pipeline

A concentrated, clinical-stage pipeline targeting CNS malignancies and glioblastoma provides strategic clarity and aligns the company with a high unmet-need therapeutic area. This focus supports durable value creation through milestone-driven de-risking and specialized expertise that investors and partners value long term.

Low financial leverage

Minimal debt reduces solvency and interest-rate exposure, preserving optionality during the clinical development cycle. Low leverage lessens near-term bankruptcy risk and gives management flexibility to pursue financing or partnerships without onerous fixed obligations, improving resilience over months.

Expanded authorized shares for capital flexibility

A materially higher authorized share count is a structural governance change that eases future equity financings, licensing equity issuances, and strategic transactions. This expands the company's ability to fund clinical programs and partnerships without repeated charter amendments, aiding long-term financing execution.

Negative Factors

No revenue; significant cash burn

Sustained negative operating and free cash flow with no product revenue creates a structural dependence on external capital to fund operations and trials. Repeated financings can dilute shareholders and divert management time, constraining execution and strategic optionality over the coming months.

Structural unprofitability and equity volatility

Ongoing deep losses and historical equity volatility (including a period of negative equity) signal weak profitability durability. This raises the risk of future dilution, limits access to non-dilutive financing, and undermines investor confidence in sustained operational self-sufficiency absent successful clinical milestones.

Leadership transition risk

A CEO transition is a meaningful structural event that can shift strategic priorities, affect clinical and financing strategies, and unsettle key external relationships. Execution and continuity risk during management change can slow program advancement or alter capital plans over the medium term.

CNS Pharmaceuticals Business Overview & Revenue Model

Company Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

How the Company Makes Money

CNS Pharmaceuticals primarily generates revenue through licensing agreements, research grants, and potential future sales of its drug candidates upon successful clinical trials and regulatory approval. The company may enter into strategic partnerships or collaborations with larger pharmaceutical companies to co-develop and commercialize its products, which can provide upfront payments, milestone payments, and royalties. Additionally, CNS Pharmaceuticals may raise capital through equity offerings to fund its research and development activities, which is a common practice in the biotechnology industry given the long development timelines and high costs associated with bringing new drugs to market.

CNS Pharmaceuticals Financial Statement Overview

Summary

Income statement and cash flow are weak with no revenue, persistent net losses, and significant TTM cash burn (~-$16.2M) implying ongoing external funding needs. Balance sheet leverage is low (minimal debt vs. equity), but historical equity volatility and negative returns indicate dilution/financing risk remains elevated.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued deep losses (net loss of about $13.1M), consistent with a pre-commercial biotech profile. Losses improved versus 2024 (about $14.9M net loss) and materially versus 2023 (about $18.9M), indicating some cost control, but the business still lacks a revenue base and remains structurally unprofitable.

Balance Sheet

Leverage is low in TTM (Trailing-Twelve-Months) with debt of roughly $31K against about $9.9M of equity (very low debt relative to equity), which reduces financial risk. However, profitability is weak with negative returns on equity, and equity has been volatile historically (including a year with negative equity in 2023), signaling potential funding/dilution risk typical for early-stage biotech companies.

Cash Flow

Cash burn remains significant: TTM (Trailing-Twelve-Months) operating and free cash flow are about -$16.2M, and free cash flow declined versus the prior year (negative growth). Cash outflows broadly track reported losses, suggesting ongoing funding needs until revenues emerge; this keeps financial flexibility dependent on external capital.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.88K	-3.31K	-4.13K	-11.76K	-13.07K	-11.10K
EBITDA	-13.05M	-14.84M	-18.86M	-15.26M	-14.47M	-9.44M
Net Income	-13.07M	-14.86M	-18.85M	-15.27M	-14.50M	-9.46M
Balance Sheet
Total Assets	11.87M	8.70M	1.70M	13.05M	8.76M	15.85M
Cash, Cash Equivalents and Short-Term Investments	9.86M	6.46M	548.72K	10.06M	5.00M	14.04M
Total Debt	30.79K	326.07K	300.81K	409.97K	387.79K	439.29K
Total Liabilities	1.96M	2.52M	6.13M	4.92M	2.14M	1.91M
Stockholders Equity	9.91M	6.18M	-4.43M	8.13M	6.62M	13.95M
Cash Flow
Free Cash Flow	-16.23M	-17.12M	-14.14M	-10.56M	-13.54M	-7.34M
Operating Cash Flow	-16.23M	-17.11M	-14.14M	-10.56M	-13.54M	-7.32M
Investing Cash Flow	-4.19K	-4.19K	-3.90K	-4.42K	-5.75K	-17.95K
Financing Cash Flow	19.13M	23.03M	4.64M	15.61M	4.51M	14.13M

CNS Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSP, the sentiment is Negative. The current price of 6.01 is below the 20-day moving average (MA) of 6.09, below the 50-day MA of 6.36, and below the 200-day MA of 8.67, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 35.59 is Neutral, neither overbought nor oversold. The STOCH value of 3.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNSP.

CNS Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNSP	46 Neutral	$3.23M	-0.09	-197.11%	―	―	99.87%
INM	44 Neutral	$2.80M	-0.14	-82.17%	―	-3.27%	51.83%
GRI	43 Neutral	$3.81M	-0.01	-238.17%	―	―	98.22%
BDRX	41 Neutral	$898.31K	-0.02	-60.37%	―	-100.00%	86.75%
OGEN	29 Underperform	$3.13M	-0.04	-168.95%	―	―	90.27%

CNS Pharmaceuticals Corporate Events

CNS Pharmaceuticals Announces New CEO Appointment

On December 16, 2025, CNS Pharmaceuticals announced a leadership transition with the appointment of Rami Levin as Chief Executive Officer and President, effective January 1, 2026. Mr. Levin brings extensive experience from leadership roles in biopharmaceutical companies and will also join the Board of Directors. His compensation package includes a base salary, performance-based bonuses, and equity grants. Additionally, the company confirmed the resignation of John Climaco from his roles as CEO and board member on December 16, 2025. Mr. Climaco’s departure is amicable, and he will receive severance benefits, including salary, bonus payments, and medical coverage.

The most recent analyst rating on (CNSP) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CNS Pharmaceuticals stock, see the CNSP Stock Forecast page.

CNS Pharmaceuticals Increases Authorized Shares for Growth

On November 17, 2025, CNS Pharmaceuticals held its Annual Meeting where stockholders approved several key proposals, including an amendment to the Articles of Incorporation to significantly increase the number of authorized shares of common and preferred stock. This move, filed on November 20, 2025, with the Nevada Secretary of State, is expected to enhance the company’s capital structure and provide greater flexibility for future growth and investment opportunities.

The most recent analyst rating on (CNSP) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CNS Pharmaceuticals stock, see the CNSP Stock Forecast page.